Negative ER Expression Assessed by 18F-FES PET/CT in the MBC With ER-positive Primary Tumor
NCT05797987 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 52
Last updated 2024-02-26
Summary
To investigate the treatment pattern and efficacy of patients with positive primary ER lesion but negative ER expression in MBC using a novel convenient way of 18F-fluoroestradiol positron emission tomography/computed tomography (18F-FES PET/CT).
Conditions
Sponsors & Collaborators
-
Fudan University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-12-01
- Primary Completion
- 2023-08-01
- Completion
- 2023-08-01
Countries
- China
Study Locations
More Related Trials
-
18F-fluoroestradiol (18F-FES) PET/CT Guided First-line Treatment for HR+/HER2- Metastatic Breast Cancer Patients
NCT06655545 ·Status: COMPLETED
-
Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer
NCT05541367 ·Status: RECRUITING
-
4FMFES-PET Imaging of ER+ Advanced Breast Cancers
NCT04824014 ·Status: RECRUITING ·Phase: PHASE2
-
Study to Determine the Utility of FES-PET in the Prediction of Response to Fulvestrant in Women With Estrogen Positive Metastatic Breast Cancer
NCT03507088 ·Status: COMPLETED ·Phase: NA
-
Relationship Between Hypoxia and Endocrine Response in Human Breast Cancer
NCT01814449 ·Status: UNKNOWN
-
Study on the Value of Non-invasive Dual-Pet Information in Subtype of Metastatic Breast Cancer
NCT04758416 ·Status: UNKNOWN
-
AR and ER Imaging in Metastatic Breast Cancer
NCT01988324 ·Status: COMPLETED ·Phase: PHASE2
-
The Role of PET/MRI in Predicting the Outcome of Definitive Chemoradiotherapy for Esophageal Cancer Patients
NCT05855278 ·Status: COMPLETED ·Phase: NA
-
Early Interim 18F-FDG-PET and 18F-FLT-PET for Predicting Treatment Response and Survival in Metastatic Breast Cancer
NCT04411966 ·Status: COMPLETED ·Phase: NA
-
The Value of 18F-FES-PET/CT in Predicting Fulvestrant Efficacy in Breast Cancer
NCT03768479 ·Status: UNKNOWN ·Phase: NA
-
Dynamic and Test-retest Whole Body [18F]FES PET Imaging in Patients With Metastatic ER+ Breast Cancer
NCT05088785 ·Status: RECRUITING ·Phase: NA
-
Fluoroestradiol PET Imaging in Predicting Response to Hormone Therapy of Breast Cancer
NCT01627704 ·Status: COMPLETED ·Phase: NA
-
[18F]FES PET/CT for the Detection of Distant Metastasis in Low-grade ER-positive Stage III Breast Cancer
NCT07314073 ·Status: RECRUITING ·Phase: PHASE2
-
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
NCT03544762 ·Status: UNKNOWN ·Phase: PHASE3
-
F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy
NCT02149173 ·Status: TERMINATED ·Phase: NA
-
18F-fluoroestradiol (FES) PET/CT for Breast Cancer
NCT04883814 ·Status: UNKNOWN ·Phase: PHASE2
-
Monitoring Response to Neoadjuvant Chemotherapy in Breast Cancer Using Ultrafast DCE-MRI
NCT05744518 ·Status: UNKNOWN
-
Study to Determine the Utility of FES-PET and FDG-PET in the Prediction of Response to Hormone Therapy in Women With Estrogen Positive Metastatic Breast Cancer
NCT00358098 ·Status: TERMINATED
-
Test - Retest Reproducibility of 18F Fluoroestradiol (FES) PET
NCT03065712 ·Status: WITHDRAWN ·Phase: PHASE2
-
FES (16α-[18F]-Fluoro-17β-estradiol)-PET: Towards a New Standard to Stage Locally Advanced and Recurrent, Estrogen Receptor Positive (ER+) Breast Cancer? Pilot Study to Compare [18F]FES-PET and [18F]FDG-PET
NCT03726931 ·Status: COMPLETED ·Phase: NA
-
A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer
NCT06557148 ·Status: RECRUITING
-
18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Breast Cancer.
NCT06335069 ·Status: RECRUITING ·Phase: PHASE2
-
FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy
NCT02398773 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
18F-FAPI-04 PET/CT and PET/MR in Patients With Various Types of Malignant Tumors
NCT06557590 ·Status: RECRUITING
-
Diagnostic Performance of [18F]FES PET/CT for Axillary LN Metastasis in ER-positive Breast Cancer
NCT06695039 ·Status: COMPLETED ·Phase: PHASE2